Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P16520
UPID:
GBB3_HUMAN
Alternative names:
Transducin beta chain 3
Alternative UPACC:
P16520; Q96B71; Q9BQC0
Background:
The Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3, also known as Transducin beta chain 3, plays a pivotal role in transmembrane signaling systems. It functions as a modulator or transducer, facilitating the GTPase activity, GDP-GTP exchange, and G protein-effector interaction. This protein's involvement in signaling pathways underscores its importance in cellular communication and response mechanisms.
Therapeutic significance:
Linked to congenital stationary night blindness, 1H, this protein's mutation highlights its critical role in visual processes. Understanding the role of Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-3 could open doors to potential therapeutic strategies for vision impairments and further elucidate the molecular mechanisms underlying night blindness.